安科生物(300009) - 2021 Q3 - 季度财报

Financial Performance - Revenue for Q3 2021 reached ¥578,153,797.21, an increase of 31.28% year-over-year, and total revenue for the first nine months was ¥1,547,398,225.09, up 34.27% compared to the same period last year[2]. - Net profit attributable to shareholders for Q3 2021 was ¥185,375,007.66, a 35.63% increase year-over-year, with a total net profit of ¥429,377,481.95 for the first nine months, reflecting a 43.58% growth[2]. - The company reported a basic earnings per share of ¥0.11 for Q3 2021, which is a 35.63% increase compared to the same period last year[2]. - Operating profit for the same period was 468.63 million RMB, an increase of 49.93% compared to the previous year[11]. - Net profit reached 398.93 million RMB, reflecting a growth of 50.36% year-on-year[11]. - The net profit for the third quarter of 2021 was CNY 431,412,232.40, an increase of 44.7% compared to CNY 297,938,392.16 in the same period last year[17]. - Operating profit reached CNY 505,190,580.99, up 42.4% from CNY 354,633,147.74 year-on-year[17]. - Total revenue from operating activities was CNY 1,481,735,309.89, a rise of 21.5% compared to CNY 1,219,724,162.66 in the previous year[20]. Cash Flow and Assets - Cash flow from operating activities for the first nine months was ¥401,587,316.25, representing a significant increase of 68.22% year-over-year[6]. - The company experienced a 50.35% decrease in cash and cash equivalents, totaling ¥123,175,327.23, primarily due to significant investments in financial products[5]. - The cash flow from operating activities generated a net amount of CNY 401,587,316.25, compared to CNY 238,727,356.26 in the same period last year, reflecting a significant increase[20]. - The company's cash and cash equivalents decreased to ¥123,175,327.23 from ¥248,066,300.57, a decline of 50.3%[14]. - Total assets as of the end of Q3 2021 amounted to ¥3,687,361,149.68, reflecting a growth of 5.21% from the end of the previous year[3]. - Current assets totaled ¥1,755,457,122.14, reflecting a growth of 6.9% from ¥1,641,349,797.47 at the end of 2020[14]. - Non-current assets increased by ¥22,515,423.31 to ¥1,886,044,483.79 as of September 30, 2021[23]. - Total liabilities stood at ¥599,678,360.01, a slight increase from ¥576,290,707.68 in the previous year[15]. Shareholder Information - The total number of common shareholders at the end of the reporting period was 87,280[7]. - The largest shareholder, Song Lihua, holds 26.52% of the shares, totaling 434,578,710 shares[7]. - Song Liming, the second-largest shareholder, owns 7.01% of the shares, amounting to 114,889,420 shares[7]. - The company has a total of 479,376,258 shares under lock-up agreements, with 360,000 shares released during the reporting period[10]. - The number of shares held by the top ten shareholders includes significant stakes from major shareholders, indicating concentrated ownership[7]. Research and Development - The company's R&D expenses for the first nine months were ¥100,716,322.52, an increase of 33.04% compared to the same period last year, indicating a commitment to enhancing research and development activities[6]. - Research and development expenses increased to ¥100,716,322.52, representing a rise of 32.9% compared to ¥75,706,095.13 in the previous year[16]. Strategic Initiatives - The company is focused on its core business and aims to stimulate vitality, leading to steady performance growth[11]. - The company plans to continue its strategic initiatives to enhance market presence and operational efficiency[11]. Financial Adjustments - The company is implementing new leasing standards starting from 2021, affecting financial statement adjustments[22]. - The company has not conducted an audit for the third quarter report[25].